EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, EyePoint intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

Guggenheim Securities is acting as sole book-running manager for the offering.

EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® (dexamethasone intraocular suspension) 9% and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18, and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures related to the advancement of EYP-1901 for retinal diseases and our other product candidates, clinical trial expenditures, acquisitions of new technologies, products or businesses in ophthalmology, and investments.